Drug intelligence / Profile preview

artemether + lumefantrine + nevirapine

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

This represents the concurrent use of artemether-lumefantrine (a fixed-dose antimalarial combination) with nevirapine (an antiretroviral medication). Artemether-lumefantrine is first-line treatment for uncomplicated malaria, while nevirapine is used in HIV therapy. When used together, significant pharmacokinetic interactions occur: nevirapine decreases artemether and dihydroartemisinin exposure but increases lumefantrine exposure. This interaction is clinically relevant for patients requiring treatment for both HIV and malaria.

Brand names: CoartemViramune
Other names: artemether-lumefantrine + nevirapinelumefantrine + artemether + nevirapine-Makerere University-malaria

Targets

CYP3A4 (Cytochrome P450 3A4)

Beyond the preview

Go deeper on artemether + lumefantrine + nevirapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on artemether + lumefantrine + nevirapine.

Explore the full profile